title: Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab.
abstract: HLA-matched unrelated donor (MUD) stem cell transplantation (MUD) is complicated by a high incidence of graft-versus-host-disease (GVHD) resulting in significant morbidity and mortality. To circumvent this problem we included alemtuzumab for in vivo and in vitro T-cell depletion in a myeloablative MUD-SCT regimen. After SCT, no severe acute GVHD was observed in the 30 transplanted patients. Donor lymphocyte infusion administered at a later time point resulted in sustained anti-tumor responses in most patients with chronic myeloid leukemia. After donor lymphocyte infusion three patients developed severe acute GVHD. Due to good responsiveness to immunosuppressive therapy only two patients developed persistent chronic GVHD. The main advantage of the transplantation regimen including alemtuzumab is that not only mortality due to GVHD is limited but also extensive chronic GVHD, which potentially leads to chronic morbidity and diminished quality of life, is hardly observed.
authors.affiliation: Dept. of Hematology, Leiden University Medical Center, Leiden, The Netherlands. P.A.von_dem_Borne@lumc.nl
authors.forename: Peter A
authors.initials: PA
authors.lastname: von dem Borne
authors.forename: Floor
authors.initials: F
authors.lastname: Beaumont
authors.forename: C W J Ingrid
authors.initials: CW
authors.lastname: Starrenburg
authors.forename: Machteld
authors.initials: M
authors.lastname: Oudshoorn
authors.forename: Geoff
authors.initials: G
authors.lastname: Hale
authors.forename: J H Frederik
authors.initials: JH
authors.lastname: Falkenburg
authors.forename: Willem E
authors.initials: WE
authors.lastname: Fibbe
authors.forename: Roel
authors.initials: R
authors.lastname: Willemze
authors.forename: Renee M Y
authors.initials: RM
authors.lastname: Barge
mesh_terms: D000293:Adolescent; D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008212:Lymphocyte Depletion / Q000379:methods*; D008297:Male; D008875:Middle Aged; D033581:Stem Cell Transplantation / Q000379:methods*; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab